Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H15N3O2S |
| Molecular Weight | 229.299 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)[C@@H](CC1=CNC(=S)N1)C([O-])=O
InChI
InChIKey=SSISHJJTAXXQAX-ZETCQYMHSA-N
InChI=1S/C9H15N3O2S/c1-12(2,3)7(8(13)14)4-6-5-10-9(15)11-6/h5,7H,4H2,1-3H3,(H2-,10,11,13,14,15)/t7-/m0/s1
| Molecular Formula | C9H15N3O2S |
| Molecular Weight | 229.299 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
ERGO (Ergothioneine) is naturally occurring antioxidant derived from the diet and abundantly contained in golden oyster mushroom (Pleurotus cornucopiae var. citrinopileatus. It is hydrophilic and membrane impermeable, but is well absorbed from the gastrointestinal tract due to the presence of a specific carrier‐mediated transport system, carnitine/organic cation transporter OCTN1/SLC22A4, essential for the beta-oxidation of fatty acids. Numerous in vitro assays have demonstrated the antioxidant and cytoprotective capabilities of ERGO against a wide range of cellular stressors, but an antioxidant role has yet to be fully verified in vivo. Nevertheless, the accumulation, tissue distribution, and scavenging properties, all highlight the potential for EGT to function as a physiological antioxidant. Because ERGO is highly distributed into the brain after oral ingestion, OCTN1 may contribute to the alleviation of oxidative stress and promotion of neuronal differentiation via the uptake of ERGO in the brain, perhaps abating symptoms of neurological disorders.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27134772
Curator's Comment: “Known to be CNS active in mouse. Human data not available
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q9H015 Gene ID: 6583.0 Gene Symbol: SLC22A4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28768995 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27134772
in mice: To clarify the exposure of ERGO (ergothioneine) to brain and the possible antidepressant‐like effect after oral ingestion, ERGO or GOME (golden oyster mushroom extract) which contains 1.2% (w/w) ERGO was mixed with feed and provided to mice for 2 weeks, and then ERGO concentration and antidepressant‐like effect were evaluated by LC‐MS/MS and FST (forced swimming test) or TST (tail suspension test), respectively.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15795384
Human OCTN1 was expressed in 293 cells. Analysis of transport efficiency of stachydrine-related solutes, affinity, and Na+ dependence indicates that the physiological substrate is ergothioneine (ET). Efficiency of transport of ET was as high as 195 μl per min per mg of protein. By contrast, the carnitine transporter OCTN2 from rat did not transport ET at all
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:06:56 GMT 2025
by
admin
on
Mon Mar 31 18:06:56 GMT 2025
|
| Record UNII |
BDZ3DQM98W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
4323 (Number of products:1)
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
||
|
FDA ORPHAN DRUG |
918722
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID901020082
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
497-30-3
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
4828
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
7175
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
734
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
BDZ3DQM98W
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
207-843-5
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
m4990
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
BDZ3DQM98W
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
1314350
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | RxNorm | ||
|
134344
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
D004880
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
82707
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
300000022775
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
ERGOTHIONEINE
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY | |||
|
5351619
Created by
admin on Mon Mar 31 18:06:56 GMT 2025 , Edited by admin on Mon Mar 31 18:06:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> INHIBITOR |